Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IMMUNE DESIGN CORP.IMDZ · Entity 158527 | Director | April 02, 2019 | April 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IMMUNE DESIGN CORP.
Report date April 02, 2019 · Filed April 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2019-04-02 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-04-02 · Disposition to issuer · Disposed 175,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration"). |
| Common stockSEC Table I · non-derivative | IndirectBy Wife's IRA | 0 |
Reported balance
After 2019-04-02 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-04-02 · Disposition to issuer · Disposed 3,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration"). |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-02 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required witholding. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-04-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required witholding. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-02 · Disposition to issuer · Disposed 12,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required witholding. F3: Not Applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration").
F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required witholding.
F3: Not Applicable.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MAGNITE, INC.
Report date April 01, 2020 · Filed April 03, 2020
Section 16 reporting ended · disclosed 2020-04-03. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2019 Filed May 17, 2019 17:58 UTC | MAGNITE, INC. RUBI · Entity 2049 | GrantCommon Stock | 19,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001595974-19-000078 · wf-form4_155813031596615.xml · nonDerivative · entry 1 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,703 F1 · shares: Represents restricted stock units that vest in full on the earliest of (i) May 15, 2020, (ii) the date of the 2020 annual meeting of the Issuer's stockholders, or (iii) a change of control of the Issuer. F2 · price: Granted as compensation for services. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:06 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 12,500 | Not disclosed Strike: $1.31 | Not disclosed |
DisclosureSEC source: 0001209191-19-023678 · doc4.xml · derivative · entry 5 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required witholding. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required witholding. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:06 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 12,500 | Not disclosed Strike: $4.05 | Not disclosed |
DisclosureSEC source: 0001209191-19-023678 · doc4.xml · derivative · entry 4 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required witholding. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required witholding. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:06 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 10,000 | Not disclosed Strike: $5.60 | Not disclosed |
DisclosureSEC source: 0001209191-19-023678 · doc4.xml · derivative · entry 3 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required witholding. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) $5.85 over (y) the exercise price payable per share, in cash, less any required witholding. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:06 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerCommon stock | 3,000 | $5.85 | $17,550.00 |
DisclosureSEC source: 0001209191-19-023678 · doc4.xml · nonDerivative · entry 2 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Wife's IRA Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration"). Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:06 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerCommon Stock | 175,000 | $5.85 | $1,023,750.00 |
DisclosureSEC source: 0001209191-19-023678 · doc4.xml · nonDerivative · entry 1 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration"). Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 20:19 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001209191-19-002661 · doc4.xml · derivative · entry 1 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-01-03 F1 · derivative.exercise_date: All shares underlying the option will vest on January 3, 2020. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 19:37 UTC | MAGNITE, INC. RUBI · Entity 2049 | GrantStock Option (right to buy) · Derivative | 9,429 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001595974-18-000086 · wf-form4_153454900996824.xml · derivative · entry 2 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,429 Underlying: Common Stock · 9,429 shares Expires 2028-08-15 F2 · price: Granted as compensation for services. F3 · derivative.exercise_date: The stock options vest in full on the earliest of (i) May 23, 2019, (ii) the date of the 2019 annual meeting of the Issuer's stockholders, or (iii) a change of control of the Issuer. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 19:37 UTC | MAGNITE, INC. RUBI · Entity 2049 | GrantCommon Stock | 7,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001595974-18-000086 · wf-form4_153454900996824.xml · nonDerivative · entry 1 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,141 F1 · shares: Represents restricted stock units that vest in full on the earliest of (i) May 23, 2019, (ii) the date of the 2019 annual meeting of the Issuer's stockholders, or (iii) a change of control of the Issuer. F2 · price: Granted as compensation for services. Read SEC document |
| January 04, 2018 Filed Jan 8, 2018 20:30 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001209191-18-002816 · doc4.xml · derivative · entry 1 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-01-04 F1 · derivative.exercise_date: All shares underlying the option will vest on January 4, 2019. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 09:15 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | PurchaseCommon Stock | 50,000 | $4.50 | $225,000.00 |
DisclosureSEC source: 0001209191-17-059345 · doc4.xml · nonDerivative · entry 1 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 175,000 Read SEC document |
| October 27, 2017 Filed Oct 31, 2017 19:00 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | PurchaseCommon Stock | 65,000 | $4.07 | $264,751.50 |
DisclosureSEC source: 0001209191-17-058490 · doc4.xml · nonDerivative · entry 1 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 125,000 F1 · price: The price reported on Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $4.00 to $4.10 on October 27, 2017. The reporting person will provide upon request to the SEC, the issuer or security holder of Issuer, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: On September 20, 2016, the reporting person filed a Form 4 which inadvertently reported that the acquisition of 50,000 shares of the Issuer's Common Stock was held directly by the reporting person. Subsequently, on December 22, 2016, the reporting person disposed of 10,000 shares. This Form 4 corrects the reporting person's holdings to reflect that the remaining 40,000 shares are held indirectly by the reporting person's trust. Read SEC document |
| July 11, 2017 Filed Jul 12, 2017 18:08 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | PurchaseCommon Stock | 2,000 | $9.33 | $18,650.00 |
DisclosureSEC source: 0001209191-17-044944 · doc4.xml · nonDerivative · entry 2 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 20,000 F2 · price: The reported price in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $9.30 to $9.35 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 18:08 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | PurchaseCommon Stock | 10,000 | $9.00 | $89,950.00 |
DisclosureSEC source: 0001209191-17-044944 · doc4.xml · nonDerivative · entry 1 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 18,000 F1 · price: The reported price in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $8.85 to $9.20 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document |
| July 07, 2017 Filed Jul 10, 2017 19:03 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | PurchaseCommon Stock | 4,000 | $9.15 | $36,600.00 |
DisclosureSEC source: 0001209191-17-044686 · doc4.xml · nonDerivative · entry 2 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 8,000 F2 · price: The reported price in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $9.10 to $9.20 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2017 Filed Jul 10, 2017 19:03 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | PurchaseCommon Stock | 4,000 | $9.39 | $37,550.00 |
DisclosureSEC source: 0001209191-17-044686 · doc4.xml · nonDerivative · entry 1 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 4,000 F1 · price: The reported price in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $9.35 to $9.45 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document |
| May 23, 2017 Filed May 25, 2017 20:32 UTC | MAGNITE, INC. RUBI · Entity 2049 | GrantStock Option (right to buy) · Derivative | 10,363 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001595974-17-000039 · wf-form4_149575870812644.xml · derivative · entry 2 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,363 Underlying: Common Stock · 10,363 shares Expires 2027-05-23 F2 · price: Granted as compensation for services. F3 · derivative.exercise_date: The stock options vest in full on the earliest of (i) May 23, 2018, (ii) the date of the next Annual Meeting of the Issuer's stockholders, or (iii) a change of control of the Issuer. Read SEC document |
| May 23, 2017 Filed May 25, 2017 20:32 UTC | MAGNITE, INC. RUBI · Entity 2049 | GrantCommon Stock | 7,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001595974-17-000039 · wf-form4_149575870812644.xml · nonDerivative · entry 1 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,849 F1 · shares: Represents restricted stock units that vest in full on the earliest of (i) May 23, 2018, (ii) the date of the next Annual Meeting of the Issuer's stockholders, or (iii) a change of control of the Issuer. F2 · price: Granted as compensation for services. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 21:00 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-17-002798 · doc4.xml · derivative · entry 1 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-04 F1 · derivative.exercise_date: The shares underlying the option will become fully vested on January 4, 2018, subject to the Reporting Person's continuous service through such date. Read SEC document |
| December 22, 2016 Filed Dec 27, 2016 20:45 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | SaleCommon Stock | 10,000 | $6.20 | $62,039.00 |
DisclosureSEC source: 0001209191-16-156857 · doc4.xml · nonDerivative · entry 1 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.15 to $6.30 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 20, 2016 Filed Sep 20, 2016 20:11 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | PurchaseCommon Stock | 40,000 | $6.25 | $250,000.00 |
DisclosureSEC source: 0001209191-16-142200 · doc4.xml · nonDerivative · entry 1 COLEMAN LEWIS W · CIK 0001216504 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.